A Single Arm Phase IV Clinical Trial to Describe the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis
Latest Information Update: 21 Apr 2023
At a glance
- Drugs Teriflunomide (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms SAFE
- Sponsors Sanofi; Sanofi-Synthelabo
Most Recent Events
- 10 May 2022 Status changed from active, no longer recruiting to completed.
- 19 Apr 2021 Status changed from recruiting to active, no longer recruiting.
- 02 Apr 2019 Planned End Date changed from 1 Dec 2021 to 1 Apr 2022.